Curocell

Curocell Equity Ratio

The Equity Ratio of Curocell (372320.KQ) as of Oct 28, 2026 is 4.58 %. In the previous year, Equity Ratio was 40.90 % — a change of -88.80% (lower).

Equity Ratio

4.58 %

YoY

-88.80%

Last updated:

Equity Ratio of Curocell is 2025 4.58 % . Equity Ratio of Curocell was 2024 40.90 % . It decreases by -88.80% lower compared to the previous year.

The Curocell Equity Ratio history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Ratio
Date
Equity Ratio
Jan 1, 2021
-14.89 KRW
Jan 1, 2022
-54.10 KRW
Jan 1, 2023
56.30 KRW
Jan 1, 2024
40.90 KRW
Jan 1, 2025
4.58 KRW
The Curocell Equity Ratio history
YEAREquity RatioYoY
4.58 %-88.80%
40.90 %-27.36%
56.30 %-204.08%
-54.10 %+263.26%
-14.89 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Curocell Stock analysis

What does Curocell do? Curocell Inc makes money through the development and commercialization of CAR-T therapy technologies for cancer treatment. The company focuses on novel chimeric antigen receptor (CAR)-T therapies targeting specific cancer antigens, improving medicinal effects, reducing side effects, and automating quality analysis. These products are developed for pharmaceutical companies and healthcare providers seeking advanced cancer treatments. The firm's R&D efforts target the biotechnology sector, specifically oncology applications. Curocell Inc's business model centers on creating innovative CAR-T therapies that address unmet medical needs in cancer care. The company's research and development activities are directed at enhancing the efficacy and safety of CAR-T treatments, which are sold to pharmaceutical firms for further development and distribution. The firm's products are positioned within the biotechnology industry, catering to the growing demand for targeted cancer therapies. The company's revenue streams come from the sale of its developed CAR-T technologies to pharmaceutical partners. These partnerships enable the commercialization of Curocell's innovations in the global oncology market. Curocell Inc operates within the biotechnology sector, specifically focusing on the development of next-generation CAR-T therapies for cancer patients. Curocell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Curocell stock

Equity Ratio of Curocell is 4.58 % in 2025.

Equity Ratio of Curocell changed from 40.90 % to 4.58 %, representing a -88.80% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Equity Ratio Curocell since 2006 – with annual values, charts, and detailed analysis.

The equity ratio measures the proportion of total assets financed by shareholders' equity. Higher ratios indicate stronger financial independence and lower leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Ratio's Curocell with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Curocell

All Key Metrics — Curocell